Corpus 1,273 assessed · 1,174 scored · 643 reproduced ≥75 · 169 flagged ·∅ 74.1/100

Publications 3 Datasets 392.5k Experiments 4.7k

Explore

Filters: Cell Rep Med ✕ medium ✕ 1 ✕ clear all

3 matching publication(s)

Publication	Journal	Year	Score	Verdict
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs. PMID 38781959	Cell Rep Med	2024	76	L1 76/100
A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: A multi-center study. ⚑ PMID 37852185	Cell Rep Med	2023	65	65/100 ⚑

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100

Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs.

PMID 38781959 · Cell Rep Med · 2024

L1 76/100

A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: A multi-center study.⚑

PMID 37852185 · Cell Rep Med · 2023

65/100 ⚑